Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Chiriax; MF-934; Monos; Qari; Rufakin; Tebraxin

Latest Information Update: 10 Jul 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mediolanum
  • Developer Bracco; Hilton Pharma; Laboratoires Leurquin-Mediolanum; Selvi Laboratorio Bioterapico; Universal Pharma Holdings
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Respiratory tract infections; Urinary tract infections

Most Recent Events

  • 10 Jul 2007 Discontinued - Phase-III for Bacterial infections in United Kingdom (PO)
  • 10 Jul 2007 Discontinued - Phase-III for Bacterial infections in USA (PO)
  • 06 Dec 2001 Registered for Bacterial infections in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top